Author(s): Chen S, Parmigiani G
Abstract Share this page
Abstract PURPOSE: Genetic counseling is now routinely offered to individuals at high risk of carrying a BRCA1 or BRCA2 mutation. Risk prediction provided by the counselor requires reliable estimates of the mutation penetrance. Such penetrance has been investigated by studies worldwide. The reported estimates vary. To facilitate clinical management and counseling of the at-risk population, we address this issue through a meta-analysis. METHODS: We conducted a literature search on PubMed and selected studies that had nonoverlapping patient data, contained genotyping information, used statistical methods that account for the ascertainment, and reported risks in a useable format. We subsequently combined the published estimates using the DerSimonian and Laird random effects modeling approach. RESULTS: Ten studies were eligible under the selection criteria. Between-study heterogeneity was observed. Study population, mutation type, design, and estimation methods did not seem to be systematic sources of heterogeneity. Meta-analytic mean cumulative cancer risks for mutation carriers at age 70 years were as follows: breast cancer risk of 57\% (95\% CI, 47\% to 66\%) for BRCA1 and 49\% (95\% CI, 40\% to 57\%) for BRCA2 mutation carriers; and ovarian cancer risk of 40\% (95\% CI, 35\% to 46\%) for BRCA1 and 18\% (95\% CI, 13\% to 23\%) for BRCA2 mutation carriers. We also report the prospective risks of developing cancer for currently asymptomatic carriers. CONCLUSION: This article provides a set of risk estimates for BRCA1 and BRCA2 mutation carriers that can be used by counselors and clinicians who are interested in advising patients based on a comprehensive set of studies rather than one specific study.
This article was published in J Clin Oncol
and referenced in Journal of Molecular and Genetic Medicine